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ABSTRACT 
Interleukin-1 (IL-1) has potent immunoregulatory and inflammatory functions. Its activity is mediated by an 
80-kDa receptor on the cell surface and leads to activation of other genes. The underlying molecular events are 
largely unknown. We investigated the role of phosphatases in activation of the IL-2 gene in EL4 thymoma cells. 
We found that the protein phosphatase PP1 and PP2A inhibitor okadaic acid (OA) alone was able to signifi-
cantly stimulate IL-2 production by the IL-1-responsive EL4 subline EL4 5D3 and also by the IL-l-nonre-
sponsive EL4 subline EL4D6/76. In the IL-l-responsive cell line OA strongly synergized with phorbol myris-
tate acetate (PMA) and IL-1. In the IL-l-nonresponsive cell line OA synergized with PMA but not with IL-1. 
Under suboptimal conditions of PMA/OA synergy an additional synergistic effect of IL-1 was shown. This was 
true for IL-2 and IL-6 production. Sphingomyelinase or sphingosine had no detectable effect. The kinetics of 
OA- and PMA-induced expression of IL-2 mRNA and IL-2 protein was different. PMA induced maximal ex-
pression between 6 and 12 h and was almost undetectable at 24 h. OA-induced expression was first obvious at 
12 h and continued longer than 36 h. In both cases IL-1 caused no shift in kinetics, but potentiated the effects 
of the different tumor promoters. Utilizing IL-2 promoter-CAT constructs we showed in transfection experi-
ments that the synergistic effect was also evident on the transcriptional level. We conclude from the data that 
phosphatases play an important role for IL-2 expression and that IL-1 can use additional pathways of activa-
tion that are different from events induced by PMA or OA. 
INTRODUCTION 
Interleukin-1 (IL-1) is a pleiotropic molecule that has im-munoregulatory and inflammatory functions [for review see 
(1)]. IL-1 activity is mediated by the two distantly related ago-
nists IL- la and IL-lß and a receptor antagonist (IL-1 Ra) with 
structural relation to the agonists. Agonists and antagonist bind 
an 80-kDa single-chain receptor (IL-1RI) primarily expressed 
on T cells and fibroblasts and a 67-kDa receptor (IL-1RII) 
mainly found on B cells and macrophages (1) with comparable 
affinity. IL-1RII is not involved in signal transduction (2,3). 
Despite many attempts over the last years the mechanism of 
signal transduction in cells after exposure to IL-1 remains 
poorly understood (4,5). After binding of IL-1 the complex is 
internalized and, depending on the cell type, transported to the 
nucleus from where it can be recovered in active form (6,7). 
There is some indication that this process is required for activ-
ity. 
We have reported that an IL-lRI-positive EL4 T cell subline 
EL4D6/76 incapable of internalization does not transmit a sig-
nal to the IL-2 promoter (8). Recently, Grenfell et al. have 
shown that mutation of the putative nuclear targeting sequence 
in IL-1 decreased IL-1 activity (9). On the other hand, large 
parts of the cytoplasmic domain of the IL-1RI could be re-
moved without abolishing internalization, although the EL-1 re-
sponse was inhibited (10,11). For the IL-1 Ru on B cells no 
such information is available since nuclear translocation was 
not observed (12). The nature of second messenger events is 
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controversial. Much of this controversy may be due to the find-
ing that only the IL-1 RI was shown to be capable of signaling, 
whereas the IL-1RII only binds IL-1 (2,3). It was shown in 
some systems that cAMP levels were elevated after exposure to 
IL-1 (13,14) and that proteinkinase A could be an important 
mediator (15), whereas in other systems no or insufficient 
changes of cAMP levels were reported (16—19). The same con-
troversy holds true for the involvement of proteinkinase C 
(20,21). The simultaneous involvement of both pathways was 
also shown (22,23). 
It is clear that phosphorylation events do occur in many cells 
after binding of IL-1. Whether this phosphorylation is essential 
for internalization or is one step in the signaling cascade cannot 
be concluded from the data available. Different substrates for 
IL-1-dependent phosphorylation have been identified. 
Phosphorylation of a 65-kDa protein was shown in peripheral 
blood mononuclear cells (19). The 27-kDa heat shock protein in 
fibroblasts and HepG2 cells (24) and the EGF receptor in fi-
broblasts and KB cells were found to be phosphorylated 
(25,26). In AtT-20 pituitary cells a group of 19- to 20-kDa cy-
tosolic proteins was found to be phosphorylated (27), as well as 
talin in fibroblasts (28) and a 41-kDa cytosolic protein in K562 
cells (29). In the IL-1-responsive D10.A Th2 helper cell line 
binding of the IL-1R activated tyrosine kinases, which resulted 
in the phosphorylation of a set of proteins of 38,75,97, and 115 
kDa (30). In Chinese hamster ovary cells transfected with the 
IL-1RI the receptor itself was phosphorylated after IL-1 stimu-
lation (31,32). IL-1-dependent alteration of the phosphorylation 
levels of microtubule-associated protein-2 kinases was also re-
ported (33). Later steps in the signaling cascade seem to involve 
the activation of the nuclear binding proteins AP-1 (34,35) and 
N F K B (36). However, the role of AP-1 as mediator of IL-1 ac-
tivity in T cells is controversial. In addition, we have shown that 
IL-1 specifically stimulated an NFKB-like nuclear factor IL-1 
NF in EL4 cells (37). It was also shown recently that a new sec-
ond messenger pathway might be involved in IL-1 signal trans-
duction. Cleavage of sphingomyelin and increase in intracellu-
lar ceramide accompanied IL-1 activity in EL4 cells and 
sphingomyelinase synergized with PMA in these cells to induce 
IL-2 production (38). 
To further investigate the role of phosphorylation events af-
ter binding of IL-1 that lead to IL-2 secretion we have em-
ployed the non-phorbol-type tumor promoter okadaic acid 
(OA). OA is a specific inhibitor of protein phosphatases PP1 
and PP2A (39) and has pronounced effects in several aspects of 
T cell activation (40-43). AP-1 may be a possible mediator of 
IL-1 activity in T cells. It was shown that the binding activity 
and the expression of AP-1 were modulated by OA alone or in 
synergistic fashion with PMA (44,45). Furthermore, OA in-
creased the stability of IL-2 mRNA in human T lymphocytes 
(46) and was able to mimic many effects of IL-1 in primary hu-
man fibroblasts (47). Recently, it was shown that OA-sensitive 
phosphatases play a role in signaling IL-2 synthesis. It was re-
ported that IL-1 leads to increased phosphorylation of PKC-ß 
whose action was potentiated by OA (48). We show in this re-
port that the expression of interleukin-2 (IL-2) by the IL-1-re-
sponsive EL4 5D3 cells was stimulated by OA on the protein 
and mRNA level and that OA synergized with PMA and with 
IL-1. We show in addition that the IL-2 promoter in EL4 was 
synergistically stimulated by OA and IL-1. We therefore con-
clude that the level of protein phosphorylation is an important 
requisite for IL-1 activity, but that the events controlled by 
phosphatases and kinases are at least in part qualitatively differ-
ent from the IL-1-mediated signal in EL4. 
MATERIALS AND METHODS 
Cells and cell culture 
The selection of the EL4 subclones EL4 5D3 and EL4D6/76 
was described by von Hoegen et al. (8). EL4 6.1 cells were ob-
tained from Dr. R. McDonald, Ludwig Institute for Cancer 
Research, Epalinges, Switzerland. Cells were cultured in RPMI 
1640 containing 10% FCS, 3 x 10-5 M 2-mercaptoethanol, 100 
IU/ml penicillin, and 100 Hg/ml streptomycin in humidified air 
at 37°C with 5% C 0 2 . If not indicated otherwise, washed cells 
were adjusted to a final density of 106 per ml and incubated for 
the indicated times with the indicated concentrations of 
reagents in culture medium at 37°C in humidified air at 37°C 
with 5% C 0 2 . At the end of the incubation period cell free su-
pernatants were removed and tested for IL-2 or IL-6. 
Alternatively, cells were collected by centrifugation and total 
cytoplasmic RNA was prepared. 
Reagents 
Phorbol myristate acetate (PMA), MTT, sphingosine, and 
sphingomyelinase from Bacillus cereus or from Staphylococcus 
aureus were all purchased from Sigma, Deisenhofen. Okadaic 
acid was obtained from Fujisawa Pharmaceutical Co., Tokyo, 
Japan, or purchased from BIOTREND Chemikalien, Köln. 
Human recombinant IL- la was kindly provided by Drs. A. 
Stern and P. Lomedico (Hoffmann-LaRoche, Nutley, NJ). The 
specific activity was 5 x 106 U/mg protein as determined by the 
lymphocyte activating factor assay. It was used at a concentra-
tion of 10 U/ml. 
Cytokine assays 
IL-2 activity in supernatants was quantitated by the ability to 
support growth of the IL-2-dependent cell line W2 as described 
(49) . Units of IL-2 are based on a standard purchased from 
Biogen (Geneva, Switzerland; Batch No. RNB85738/09Y). 
IL-2 titers were measured at concentrations of OA that had no 
adverse effect on the assay procedure. IL-6 activity in super-
natants was quantitated by the ability to support growth of the 
IL-6-dependent cell Une B9. One U/ml was defined as the con-
centration of IL-6 yielding half-maximal proliferation of 
3000-4000 cells per well after 72 h of culture. In both assays, 
either [3H]thymidine incorporation or MTT conversion was 
used for measurement of proliferation. Both methods gave 
comparable results. 
RNA extraction and hybridization procedures 
Cytoplasmic RNA was prepared by the method of Gough 
(50) . RNA was denatured with formaldehyde and separated in a 
1% agarose gel and blotted on positively charged nylon mem-
branes (BNBZF3R, Pall, Dreieich, FRG). UV-fixed blots were 
stained with methylene-blue to ensure efficient transfer and 
equal loading of lanes. Probe labeling and hybridization were 
performed as described (49). The probe for mouse IL-2 was 
generously provided by A. Schimpl (Würzburg, FRG) and con-
tains the complete exon 4 of the IL-2 gene. Hybridized blots 
were exposed to X-ray films for 1 to 3 days. 
Transfections 
EL4 5D3 cells were grown to a density of about 4 x 105 
cells/ml. Cells (1.4 x 107) were transfected with 10 ug pIL 
2-293 plasmid (37) DNA in a final volume of 1.2 ml using the 
DEAE Dextran procedure (51). Two days after transfection 
cells were divided into aliquots and stimulated as above. After 
15 h of stimulation the cell lysates were assayed for chloram-
phenicol acetyltransferase (CAT) activity as described. The 
conversion of [14C]chloramphenicol to its acetylated forms was 
quantified using an automatic thin-layer chromatography linear 
analyzer (Berthold, Wildbad, Germany). The protein concen-
tration of cell extracts was measured according to Bradford and 
was used to normalize CAT activity. In addition, the plasmid 
pTKCAT21A was used as standard for transfection efficiency 
in each experiment. Plasmid pBLCAT2 was used as negative 
control and was uninducible after transfection but showed a 
very low basal transcriptional activity (37). 
RESULTS 
Okadaic acid stimulates IL-2 production in EL4 cells 
It has been shown by many investigators that for activation 
of the IL-2 gene in cells of the T cell lineage activation of the 
PKC pathway is required. We therefore investigated whether 
inhibition of dephosphorylation would lead to IL-2 gene tran-
scription. The non-phorbol tumor promoter OA has specificity 
for the protein phosphatases ppl and pp2a and was shown to be 
active in T cells in inducing AP-1 activity and expression 
(44,45). The IL-1 responsive EL4 5D3 and EL4 6.1 cells (8) 
were stimulated with increasing concentrations of OA for 24 h. 
Supernatants were then removed and tested for IL-2 concentra-
tion in a bioassay. Figure 1 shows that the response of both cell 
lines was dose dependent. Concentrations higher than 250 nM 
were toxic to the cells and morphological signs of toxicity were 
already evident at 100 nM concentrations (data not shown). 
Synergy of OA with PMA and IL-1 
Since PMA as activator of PKC induces IL-2 production in 
EL4 cells it was tested whether OA and PMA synergized as 
costimulators. EL4 5D3 cells were stimulated for 24 h in vary-
ing concentrations of PMA and OA and mixtures thereof. As 
shown in Fig. 2A strong synergy was observed. Optimal stimu-
lation for IL-2 production was achieved at 60 nM OA plus 16 
ng/ml of PMA with a stimulation index [(PMA + OA)/PMA + 
OA] of 69. Al l other combinations were less effective. The rea-
son for the decline of the dose-response curves at higher con-
centrations of OA at a given concentration of PMA was not in-
vestigated further. On visual inspection of the culture wells it 
correlated with the number of dead cells. 
It was shown by us and others that in certain EL4 cell lines 
PMA and IL-1 synergize for IL-2 production. We therefore 
tested whether this was also true for the combination of OA and 
IL-1. EL4 5D3 cells were stimulated for 24 h with graded con-
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FIG. 1. Stimulation of EL4 5D3 and EL4 6.1 cells with OA. 
Cells were cultured at 106/ml in culture medium with the indi-
cated concentrations of OA for 18 h. Cell-free supernatants 
were removed and the IL-2 concentration was measured with 
an IL-2-dependent cell line as described in Materials and 
Methods. 
centrations of OA with or without 10 U/ml of rhIL-la. As can 
be seen in Fig. 2B there was a strong synergistic effect at an op-
timal concentration of OA of 60 nM. Also, as in Fig. 2A, further 
increase of OA concentration led to decreasing production of 
IL-2. 
Expression of IL-6 protein was also synergistically stimu-
lated by IL-1 in the presence of OA or PMA. Cells were stimu-
lated for 24 h with OA, PMA, or IL-1 and mixtures thereof. 
IL-2 and IL-6 secreted into the supernatants were measured in 
bioassays. As shown in Table 1, IL-1 alone did not stimulate se-
cretion. PMA and OA alone were effective. Their combination 
with IL-1 had the expected synergistic effect for both cytokines. 
The combination of OA and PMA also acted synergistically. 
Interestingly, under the conditions of the assay, the combina-
tion of all three stimuli showed a very strong synergy for both 
cytokines, pointing to the interpretation that IL-1, OA, and 
PMA, respectively, were each using a different signaling path-
way. 
Time course of activation by okadaic acid 
To investigate the mode of action of okadaic acid more pre-
cisely, time course experiments were performed. At the initia-
tion all cultures were stimulated with the indicated agents and 
the respective culture supernatants were harvested at the indi-
cated times (3, 6,12, 24, and 48 h) and their IL-2 concentration 
was measured (Fig. 3, right panel). A big difference in the ki-
netics of the response becomes evident from the Fig. 3. 
Whereas the response to PMA reached almost maximal levels 
at 12 h, the response to OA developed much slower. Only low 
titers were detected at 12 h, but steadily increasing titers were 
monitored at 24 and 48 h. The addition of IL-1 did not change 
the kinetics of the response. Also notable was the fact that the 
synergistic effect of IL-1 with PMA was already obvious at 6 h 
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FIG. 3. Kinetics of synergistic activation of EL4 5D3 cells 
for IL-2 mRNA and IL-2 protein expression. Cells were incu-
bated in separate cultures for 3, 6, 12, 24, and 48 h with PMA, 
OA, or IL-1 alone or with the combinations of PMA + IL-1 or 
OA + IL-1. The cell density was 106 per ml except at 48 h 
where cell density was reduced to 5 x 105 per ml. At the indi-
cated times cells were collected by centrifugation. From the cell 
pellet RNA was prepared and subjected to Northern analysis. 
The left half of the figure shows the autoradiographs of the 
blots after probing with a mouse IL-2 probe. Equal loading of 
the blots was ascertained by methylene-blue staining. Al l sig-
nals had approximately equal intensity except the OA stimula-
tion signal at 24 h, which had about 0.5x the intensity of the 
other signals. The right half of the figure shows the IL-2 titers 
in the supernatants of the same cells measured as described in 
Materials and Methods. The concentrations of the reagents 
were PMA 10 ng/ml; OA 120 nM; IL-1 10 U/ml. 
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FIG. 4. OA and IL-1 synergistically activate the mouse IL-2 
promoter. EL4 5D3 cells were transfected with pIL2-293 that 
contains the minimal promoter sequence from the mouse IL-2 
gene in front of the CAT gene as reporter gene. Two days later 
cells were divided in aliquots and stimulated for 18 h with the 
indicated concentrations of OA with or without IL-1 (10 U/ml). 
CAT activity in the lysates of the cells was quantitated as de-
scribed in Materials and Methods. The numbers in brackets rep-
resent the stimulation index SI = (OA + IL-l)/OA. IL-1 alone 
had no effect above background. 
used at concentrations from 1 U/ml to 10~5 U/ml and sphingo-
sine at 50 and 10 \\M. In all experiments PMA or OA showed 
strong synergy with IL-1. However, neither at optimal nor at 
suboptimal concentrations of these reagents did we detect any 
activity of sphingomyelinase or sphingosine. 
DISCUSSION 
The initiation of T cell activities in immune responses re-
quires the activity of IL-1 as a costimulator. We have previ-
ously shown that CD4-CD8- thymocytes were costimulated by 
cells were stimulated with optimal doses of PMA + OA with or 
without IL-1 and Northern blots were hybridized with an IL-2 
probe. At 6 h clearly more IL-2 mRNA was detected in the 
presence of IL-1 than in its absence. There was no detectable 
difference at later times. When the hybridization signals were 
evaluated by densitometry the stimulation index at 6 h was 3.1 
and 1.0 at 18 h and 24 h, respectively. This again suggested a 
qualitative difference in the signals delivered by OA and IL-1. 
Since sphingomyelin was shown to be involved in IL-1 sig-
naling in EL4 cells, we were inclined to postulate that IL-1 and 
sphingomyelinase should act either additively or synergistically 
with PMA or OA. Using sphingomyelinases from 2 different 
sources and sphingosine in combination with PMA, OA and/or 
IL-1 EL4 5D3 cells were stimulated at densities ranging be-
tween 0.8 x 106/ml and 1.5 x 106/ml for 18 to 24 h and the IL-2 
produced was measured in a bioassay. Sphingomyelinase was 
TABLE 2. L A C K OF SYNERGY BETWEEN OA AND IL-1 
IN E L 4 D 6 / 7 6 CELLS 
Stimulus0 IL-2 titer* 
PMA OA No 
(ng/ml) (nM) IL-1 + IL-1' 
_ 30 <0.1 <0.1 
— 60 1 1 
16 — 2 3 
16 30 61 43 
16 60 520 565 
aIL-l-nonresponsive EL4D6/76 cells were stimulated at a concentra-
tion of 106/ml for 20 h with the stimuli at the indicated concentrations. 
bIL-2 titers in the supernatants were estimated using an IL-2-depen-
dent cell line as described in Materials and Methods. 
CIL-1 was used at a concentration of 10 U/ml. 
A 
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FIG. 2. Synergistic stimulation of EL4 5D3 cells by OA and 
PMA or IL-1 for IL-2 production. EL4 5D3 cells were incu-
bated at a density of 106/ml for 24 h in 1 ml cultures. Cell-free 
supernatants were removed and the IL-2 concentration was 
measured with an IL-2-dependent cell line as described in 
Materials and Methods. (A) For stimulation OA and PMA were 
used alone at the indicated concentrations. For test of synergy 
OA and PMA were mixed so that the indicated final concentra-
tions were achieved. (B) The indicated concentrations of OA 
with or without 10 U/ml of IL-1 were used for stimulation. 
Controls: no stimulation <0.1 U/ml; PMA (10 ng/ml) 19 U/ml; 
PMA + IL-1 (10 U/ml) 1126 U/ml. 
and fully developed at 12 h. This again suggested that OA and 
IL-1 can use independent signal transduction pathways. 
To determine whether the activities of OA were reflected at 
the transcriptional level Northern blots were prepared using to-
tal cytoplasmic RNA from cells that were stimulated as shown 
in Fig. 3. The blots were hybridized to an IL-2 probe and au-
toradiographed. As shown in Fig. 3 (left panel), the differences 
between the different modes of stimulation were even more 
striking. Stimulation with PMA + IL-1 gave rise to the appear-
ance of significant amounts of IL-2 mRNA already at 3 h, 
demonstrating the very quick synergistic effect of DL-1. No IL-
2 mRNA was seen in cells stimulated with OA or OA + IL-1 
until after 12 h stimulation. Whereas the effect of PMA stimu-
TABLE 1. SYNERGISTIC INDUCTION OF IL-2 AND IL-6 
SECRETION BY OA, PMA, AND IL-1 
Stimuli" IL-2 titers (U/ml)b IL-6 titers (U/ml)c 
None <0.1 <0.1 
PMA (5 ng/ml) 3 1 
OA(125nM) 12 90 
IL-1 (10 U/ml) <0.1 <0.1 
PMA + IL-1 26 40 
OA + IL-1 66 3500 
PMA + OA 494 2400 
PMA + OA + IL-1 >2000 >22000 
aEL4 5D3 cells were stimulated for 24 h at a concentration of 106 per 
ml with the indicated agents. When combined stimuli had the same con-
centrations as when used alone. 
bIL-2 titers represent international standard. 
cIL-6 titers were estimated as described in Materials and Methods. 
One unit per ml causes 50% maximal MTT conversion. 
lation had mostly disappeared at 24 h, OA-induced production 
of IL-2 mRNA expression was still detected at 48 h. 
The late onset of IL-2 mRNA appearance and the persistence 
of IL-2 mRNA could be explained by posttranslational activity 
of OA leading to increased stability of IL-2 mRNA as reported 
for T cells (46). Alternatively, the transcriptional activity could 
be affected. To discriminate between the two possibilities and 
to investigate whether OA might be active on the transcrip-
tional level, EL4 5D3 cells were transiently transfected with the 
plasmid pIL2-293 that contained the first 293 bp of the mouse 
IL-2 promoter in front of the CAT gene as reporter gene. 
Transfected cells were stimulated with graded doses of OA 
with or without IL-1. Eighteen hours later CAT activity was de-
termined in the cell lysates. Figure 4 shows that OA alone only 
weakly stimulated CAT expression. Strong synergistic stimula-
tion was observed in the presence of IL-1 leading to stimulation 
indices (SI) as high as 9.9, demonstrating strong activity of OA 
on the transcriptional level. 
To further dissect the roles of IL-1 and OA IL-2 production 
of the IL-l-nonresponsive cell line, EL4D6/76 was tested after 
stimulation for 20 h with PMA, OA, and several combinations 
of these agents. As seen from Table 2, OA was able to weakly 
induce EL4D6/76 by itself but strongly synergized with PMA. 
There was no synergy of OA or PMA with IL-1 detectable. The 
IL-2 levels reached with PMA and OA together were also not 
further enhanced by the addition of IL-1. This lack of additive 
or synergistic effects suggests that OA may have some activi-
ties in common with IL-1 as reported, but does not substitute 
for the defect of EL4D6/76. This again indicates that IL-1 acti-
vates additional pathways. 
In experiments evaluating the synergy between OA and 
PMA we had observed that at concentrations of PMA and OA 
yielding maximal production of IL-2 there was no additional ef-
fect of IL-1. To determine whether under such conditions both 
agents together completely replace IL-1 the time course of IL-1 
activity under these conditions was investigated. Since OA by 
itself acted rather late but the synergy with IL-1 was observed 
very early after activation early time points were investigated. 
The data in Fig. 5 show that this indeed was the case. EL4 5D3 
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FIG. 5. Kinetic of IL-2 mRNA expression and IL-1-depen-
dent synergy with PMA and OA at optimal stimulation condi-
tions. EL4 5D3 cells at a density of 106/ml were stimulated for 
6,12, and 24 h with optimal concentrations of PMA (32 ng/ml) 
+ OA (60 nM) with or without IL-1 (10 U/ml). Cells were col-
lected by centrifugation and RNA was prepared. Northern blots 
were prepared and probed with an IL-2 probe as described in 
Fig. 3. 
IL-1 to express de novo functional IL-1 receptors (49). Others 
have shown that IL-1 is needed for the production of IL-2. 
Utilizing IL-1-responsive and IL-l-nonresponsive subclones of 
the murine thymoma EL4 we have shown that IL-1 enhances 
the activity of the IL-2 promoter and that this enhancement was 
due to the specific activation by IL-1 of the NFicB-like factor 
IL-1 NF that binds to the TCEd element of the promoter (37). 
Yet, relatively little is known about the messengers involved in 
this activation cascade. In this report we investigated whether 
serine/threonine phosphatases would be involved in IL-1 sig-
naling. We found that in contrast to IL-1 alone the ppl and pp2a 
serine/threonine phosphatase inhibitor OA alone was capable of 
inducing IL-2 production. Since there was indication in the lit-
erature showing qualitatively comparable effects of IL-1 and 
okadaic acid (44,45,47,52), we looked at the effect of combin-
ing the two reagents expecting synergistic or additive activities. 
We found strong synergy with respect to IL-2 or IL-6 produc-
tion over a wide range of OA concentration. This led us to con-
clude that even though OA shares many effects with IL-1, some 
pathways induced by IL-1 may be different from the ones in-
duced by OA. Several other lines of evidence also point to this 
interpretation. In contrast to OA, which activated EL4 cells 
very slowly compared to PMA IL-1 activity was rapidly 
demonstrable. In synergy with PMA or OA or both the costim-
ulatory effect was evident at the earliest time points. OA was 
also active in the IL-l-nonresponsive cell line EL4 D6/76. 
Although OA mimics early effects of IL-1, these effects do not 
comprise all of the activities of IL-1 since one should have ex-
pected restoration of the defective IL-1 responsiveness of this 
cell line. However, it is possible that OA and IL-1 share some 
pathways later in the signaling cascade. It could be speculated 
that the presence of internalized IL-1 is required for activation 
of the IL-2 promoter. Since internalization of the IL-1/IL-1R 
complex alone was shown not to be sufficient for IL-2 promoter 
activation (11), it would be interesting to test whether intracel-
lularly expressed IL-1 synergizes with OA or whether comple-
mentation and synergy between the truncated, internalized, but 
inactive IL-1R and OA exists. Furthermore, we tested whether 
the additional pathway of IL-1 activity could be the recently de-
scribed sphingomyelin pathway, which would explain the syn-
ergistic effects shown (38). However, we found no activity of 
sphingomyelinase or sphingosine in our system. The discrepan-
cies between our results and the published findings may be due 
to the EL4 cells used, which were not further characterized. 
Another possibility could be the difference in sensitivity of de-
tection of produced IL-2. We used an IL-2-specific bioassay 
with a detection limit of 0.1 U/ml, whereas Mathias et al tested 
IL-2 by ELISA (38). 
It was shown by others that OA increased the stability of IL-
2 mRNA in human T cells (46). The slow accumulation and the 
long duration of IL-2 mRNA expression after OA stimulation 
shown in this paper fits this finding. Nevertheless, it is unlikely 
that this is the mechanism of OA action. We found that the tran-
scription of the transfected IL-2 promoter was enhanced by OA 
and that IL-1 synergistically increased this transcription. In ad-
dition, in experiments not shown in this paper, we found that in 
EL4 cells the IL-2 mRNA showed no detectable decay within 8 
h. Therefore, it can be concluded that the activity of OA leads to 
increased transcription of the IL-2 gene. 
The target sequences on the IL-2 promoter were not investi-
gated. It was shown that OA stimulated expression and binding 
activity of the transcription factor AP-1 in EL4 (45). However, 
there was almost no synergy between OA and IL-1 in this re-
spect, which is in contrast to the effect found on the promoter in 
our experiments shown in this report. There is also evidence by 
us and others that AP-1 is not a major contributor to the effec-
tive stimulation of the IL-2 promoter by IL-1 costimulation 
(37,53-55). It can be expected, therefore, that the increased 
transcription was due to activation of sites different from the 
AP-1 binding site. 
It is also very unlikely that modulation of IL-1R expression 
plays a role in OA stimulation in contrast to the TNFR, where 
down-modulation and shedding was observed (56). Since less 
than 20 IL-1R per cell are sufficient for activation (3) up- or 
down-regulation of the approximately 2500 receptors may not 
effectively influence activation. 
Taken together, we believe that a high level of cellular pro-
tein phosphorylation, which is brought about by the synergistic 
action of PMA and OA, is a prerequisite for high level IL-2 ex-
pression. We have also preliminary evidence that any change in 
steady-state phosphorylation can prime the cell for a second 
stimulus. We found synergy between staurosporine, an in-
hibitor of PKC action, and IL-1 in stimulation of IL-2 synthesis, 
although the amount of protein produced was low (1-3 U/ml). 
Undoubtedly, IL-1 itself induces phosphorylation processes 
that use the same pathways as the substrates of OA, but IL-1 
also induces additional events. The observed nuclear transloca-
tion of the ligand-receptor complex might be of importance in 
this respect. It is conceivable that IL-1 itself and structures of 
the cytoplasmic part of the IL-1RI have to interact with the nu-
clear membrane to properly activate or induce the IL-1-specific 
nuclear factor IL-1 NF. Experiments to tackle this question are 
underway. 
ACKNOWLEDGMENTS 
The expert technical assistance of Uschi Silberzahn is grate-
fully acknowledged. We thank Daniela N . Männel for critical 
reading of the manuscript. This work was in part supported by a 
grant from the Deutsche Forschungsgemeinschaft to W.F. 
REFERENCES 
1. Dinarello, C. A. 1991. Interleukin-1 and interleukin-1 antagonism. 
Blood 77:1627. 
2. Colotta, F., F. Re, M . Muzio, R. Bertini, N. Polentarutti, M . 
Sironi, J. G. Giri, S. K. Dower, J. E. Sims, and A. Mantovani. 
1993. Interleukin-1 type II receptor: A decoy target for IL-1 that is 
regulated by IL-4. Science 261:472. 
3. Sims, J. E., M . A. Gayle, J. L. Slack, M . R. Alderson, T. A. 
Bird, J. G. Giri, F. Colotta, F. Re, A. Mantovani, K. Shanebeck, 
K. H. Grabstein, and S. K. Dower. 1993. Interleukin 1 signaling 
occurs exclusively via the type I receptor. Proc. Natl. Acad. Sei. 
U.SA. 90:6155. 
4. O'Neill, L. A., T. A. Bird, and J. Saklatvala. 1990. How does in-
terleukin 1 activate cells? Interleukin 1 signal transduction [com-
ment] [see comments]. Immunol. Today 11:392. 
5. Mizel, S. B. 1990. How does interleukin 1 activate cells? Cyclic 
AMP and interleukin 1 signal transduction [see comments]. 
Immunol. Today 11:390. 
6. Grenfell, S., N. Smithers, K. Miller, and R. Solan. 1989. 
Receptor-mediated endocytosis and nuclear transport of human in-
terleukin 1 alpha. Biochem. J. 264:813. 
1. Curtis, B. M . , M . B. Widmer, P. DeRoos, and E. E. 
Qwarnstrom. 1990. IL-1 and its receptor are translocated to the 
nucleus. J. Immunol. 144:1295. 
8. Von Hoegen, I., W. Falk, G. Kojouharof, and P. H. Krammer. 
1989. Internalization of interleukin-1 (IL-1) correlates with IL-1-
induced IL-2 receptor expression and IL-2 secretion of EL4 thy-
moma cells. Eur. J. Immunol. 19:329. 
9. Grenfell, S., N. Smithers, S. Witham, A. Shaw, P. Graber, and 
R. Solari. 1991. Analysis of mutations in the putative nuclear lo-
calization sequence of interleukin-1 beta. Biochem. J. 280:111. 
10. Heguy, A., C. T. Baldari, G. Macchia, J. L. Telford, and M . 
Melli. 1992. Amino acids conserved in interleukin-1 receptors (IL-
lRs) and the Drosophila toll protein are essential for IL-1R signal 
transduction. / . Biol. Chem. 267:2605. 
11. Heguy, A., C. Baldari, K. Bush, R. Nagele, R. C. Newton, R. J. 
Robb, R. Horuk, J. L. Telford, and M. Melli. 1991. 
Internalization and nuclear localization of interleukin 1 are not suf-
ficient for function. Cell Growth Differ. 2:311. 
12. Horuk, R. 1991. Differences in internalization and intracellular 
processing of interleukin-1 associated with the two forms of inter-
leukin-1 receptor found in B-cells and T-cells. Biochem. J. 273:79. 
13. Renkonen, R., P. Mattila, P. Hayry, and J. Ustinov. 1990. 
Interleukin 1-induced lymphocyte binding to endothelial cells. 
Role of cAMP as a second messenger. Eur. J. Immunol. 20:1563. 
14. Shirakawa, F., U. Yamashita, M. Chedid, and S. B. Mizel. 1988. 
Cyclic AMP—an intracellular second messenger for interleukin 1. 
Proc. Natl. Acad. Sei. U. S. A. 85:8201. 
15. Chedid, M. and S. B. Mizel. 1990. Involvement of cyclic AMP-
dependent protein kinases in the signal transduction pathway for 
interleukin-1. Mol. Cell Biol. 10:3824. 
16. Bomsztyk, K., B. Toivola, D. W. Emery, J. W. Rooney, S. K. 
Dower, N. A. Rachie, and C. H. Sibley. 1990. Role of cAMP in 
interleukin-1-induced kappa light chain gene expression in murine 
B cell line. J. Biol. Chem. 265:9413. 
17. Didier, M., C. Aussei, C. Pelassy, and M. Fehlmann. 1988. IL-1 
signaling for IL-1 production in T cells involves a rise in phos-
phatidylserine synthesis. J. Immunol. 141:3078. 
18. Nakano, T., O. Ohara, H. Teraoka, and H. Arita. 1990. Group II 
phospholipase A2 mRNA synthesis is stimulated by two distinct 
mechanisms in rat vascular smooth muscle cells. FEBS Lett. 
261:171. 
19. Shiroo, M. and K. Matsushima. 1990. Enhanced phosphorylation 
of 65 and 74 kDa proteins by tumor necrosis factor and interleukin-
1 in human peripheral blood mononuclear cells. Cytokine 2:13. 
20. Raz, A., A. Wyche, and P. Needleman. 1989. Temporal and phar-
macological division of fibroblast cyclooxygenase expression into 
transcriptional and translational phases. Proc. Natl. Acad. Sei. 
U.S.A. 86:1657. 
21. Zucali, J. R., C. Morse, and C. A. Dinarello. 1990. The role of 
protein kinase C in interleukin 1 and tumor necrosis factor alpha in-
duction of fibroblasts to produce and release granulocyte-
macrophage colony-stimulating activity. Exp. Hematol. 18:888. 
22. Case, J. P., R. Lafyatis, G. K. Kumkumian, E. F. Remmers, and 
R. L. Wilder. 1990. IL-1 regulation of transin/stromelysin tran-
scription in rheumatoid synovial fibroblasts appears to involve two 
antagonistic transduction pathways, an inhibitory, prostaglandin-
dependent pathway mediated by cAMP, and a stimulatory, protein 
kinase C-dependent pathway. J. Immunol. 145:3755. 
23. Munoz, E., U. Beutner, A. Zubiaga, and B. T. Huber. 1990. IL-
1 activates two separate signal transduction pathways in T helper 
type II cells. J. Immunol. 144:964. 
24. Kaur, P., W. J. Welch, and J. Saklatvala. 1989. Interleukin 1 and 
tumour necrosis factor increase phosphorylation of the small heat 
shock protein. Effects in fibroblasts, Hep G2 and U937 cells. FEBS 
Lett. 258:269. 
25. Bird, T. A., and J. Saklatvala. 1990. Down-modulation of epider-
mal growth factor receptor affinity in fibroblasts treated with inter-
leukin 1 or tumor necrosis factor is associated with phosphoryla-
tion at a site other than threonine 654. J. Biol. Chem. 265:235. 
26. Bird, T. A., and J. Saklatvala. 1989. IL-1 and TNF transmodulate 
epidermal growth factor receptors by a protein kinase C-indepen-
dent mechanism. J. Immunol. 142:126. 
27. Fagarasan, M. O., J. F. Bishop, M. S. Rinaudo, and J. Axelrod. 
1990. Interleukin 1 induces early protein phosphorylation and re-
quires only a short exposure for late induced secretion of beta-en-
dorphin in a mouse pituitary cell line. Proc. Natl. Acad. Sei. U.S.A. 
87:2555. 
28. Qwarnstrom, E. E., S. A. MacFarlane, R. C. Page, and S. K. 
Dower. 1991. Interleukin 1 beta induces rapid phosphorylation and 
redistribution of talin: A possible mechanism for modulation of fi-
broblast focal adhesion. Proc. Natl. Acad. Sei. U.S.A. 88:1232. 
29. Martin, M., D. H. Lovett, M. Szamel, and K. Resch. 1989. 
Characterization of the interleukin-1-induced tyrosine phosphory-
lation of a 41-kDa plasma membrane protein of the human tumor 
cell line K 562. Eur. J. Biochem. 180:343. 
30. Munoz, E., A. Zubiaga, C. Huang, and B. T. Huber. 1992. 
Interleukin-1 induces protein tyrosine phosphorylation in T cells. 
Eur. J. Immunol. 22:1391. 
31. Gallis, B., K. S. Prickett, J. Jackson, J. Slack, K. Schooley, J. E. 
Sims, and S. K. Dower. 1989. IL-1 induces rapid phosphorylation 
of the IL-1 receptor. J. Immunol. 143:3235. 
32. Bird, T. A., A. Woodward, J. L. Jackson, S. K. Dower, and J. E. 
Sims. 1991. Phorbol ester induces phosphorylation of the 80 kilo-
dalton murine interleukin 1 receptor at a single threonine residue. 
Biochem. Biophys. Res. Commun. 177:61. 
33. Bird, T. A., P. R. Sleath, P. C. deRoos, S. K. Dower, and G. D. 
Virca. 1991. Interleukin-1 represents a new modality for the acti-
vation of extracellular signal-regulated kinases/microtubule-asso-
ciated protein-2 kinases. J. Biol. Chem. 266:22661. 
34. Muegge, K., M. Vila, G. L. Gusella, T. Musso, P. Herrlich, B. 
Stein, and S. K. Durum. 1993. Interleukin 1 induction of the c-jun 
promoter. Proc. Natl Acad. Sei. U.S.A. 90:7054. 
35. Muegge, K., T. M. Williams, J. Kant, M. Karin, R. Chiu, A. 
Schmidt, U. Siebenlist, H. A. Young, and S. K. Durum. 1989. 
Interleukin-1 costimulatory activity on the interleukin-2 promoter 
via AP-1. Science 246:249. 
36. Bomsztyk, K., J. W. Rooney, T. Iwasaki, N. A. Rachie, S. K. 
Dower, and C. H. Sibley. 1991. Evidence that interleukin-1 and 
phorbol esters activate NF-kappa B by different pathways: role of 
protein kinase C. Cell Regul 2:329. 
37. Strieker, K., E. Serfling, P. H. Krammer, and W. Falk. 1993. 
An NF-kappaB-like element plays an essential role in interleukin-
1-mediated costimulation of the mouse interleukin-2 promoter. 
Eur. J. Immunol. 23:1475. 
38. Mathias, S., A. Younes, C.-C. Kan, I. Orlow, C. Joseph, and R. 
N. Kolesnick. 1993. Activation of the sphingomyelin signaling 
pathway in intact EL4 cells and in a cell-free system by IL-lß. 
Science 259:519. 
39. Haystead, T. A., A. T. Sim, D. Carling, R. C. Honnor, Y. 
Tsukitani, P. Cohen, and D. G. Hardie. 1989. Effects of the tu-
mour promoter okadaic acid on intracellular protein phoshorylation 
and metabolism. Nature (London) 337:78. 
40. Amaral, M. C, A. M. Casillas, and A. E. Nel. 1993. Contrasting 
effects of two tumour promoters, phorbol myristate acetate and 
okadaic acid, on T-cell responses and activation of p42 MAP-ki-
nase/ERK-2. Immunology 79:24. 
41. Miron, S., R. Hershkoviz, I. Tirosh, Y. Schechter, A. Yayun, 
and O. Lider. 1992. Involvement of a protein kinase C and protein 
phosphatases in adhesion of CD4+ T cells to and detachment from 
extracellular matrix proteins. Cell Immunol 144:182. 
42. Samstag, Y., A. Bader, and S. C. Meuer. 1991. A serine phos-
phatase is involved in CD2-mediated activation of human T lym-
phocytes and natural killer cells. J. Immunol. 147:788. 
43. Tada, Y., S. Yoshizawa, K. Nagasawa, I. Furugo, T. Tsuru, T. 
Mayumi, H. Tsukamoto, and Y. Niho. 1992. Okadaic acid en-
hances human T cell activation and phosphorylation of an internal 
substrate induced by phorbol myristate acetate. Immuno-
pharmacology 24:17. 
44. Thevenin, C, S. J. Kim, and J. H. Kehrl. 1991. Inhibition of pro-
tein phosphatases by okadaic acid induces API in human T cells. / . 
Biol. Chem. 266:9362. 
45. Chedid, M., B. K. Yoza, J. W. Brooks, and S. B. Mizel. 1991. 
Activation of AP-1 by IL-1 and phorbol esters in T cells. Role of 
protein kinase A and protein phosphatases. / . Immunol. 147:867. 
46. Ohmura, T., and K. Onoue. 1990. Stability of IL-2 mRNA in T 
lymphocytes is controlled by a protein kinase C-regulated mecha-
nism. Int. Immunol. 2:1073. 
Al. Guy, G. R., X. Cao, S. P. Chua, and Y. H. Tan. 1992. Okadaic 
acid mimics multiple changes in early protein phosphorylation and 
gene expression induced by tumor necrosis factor or interleukin-1. 
J. Biol. Chem. 267:1846. 
48. Kracht, M., A. Heiner, K. Resch, and M. Szamel. 1993. 
Interleukin-1-induced signaling in T-cells. Evidence for the in-
volvement of phosphatases PP1 and PP2A in regulating protein ki-
nase C-mediated protein phosphorylation and interleukin-2 synthe-
sis. J. Biol. Chem. 268:21066. 
49. Falk, W., D. N. Männel, H. Darjes, and P. H. Krammer. 1989. 
Interleukin-1 induces high-affinity Interleukin-2 receptor expres-
sion of CD4-8-thymocytes. J. Immunol. 143:513. 
50. Gough, N. M. 1988. Rapid and quantitative preparation of cyto-
plasmic RNA from small numbers of cells. Anal. Biochem. 173:93. 
51. Sambrook, J., E. F. Fritsch, and T. Maniatis. 1989. Molecular 
Cloning. A Laboratory Manual. Cold Spring Harbor Laboratory 
Press, Cold Spring Harbor, New York. 
52. Guy, G. R., S. P. Chua, N. S. Wong, S. B. Ng, and Y. H. Tan. 
1991. Interleukin 1 and tumor necrosis factor activate common 
multiple protein kinases in human fibroblasts. J. Biol. Chem. 
266:14343. 
53. Durand, D. B., J. P. Shaw, M. R. Bush, R. E. Replogle, R. 
Belagaje, and G. R. Crabtree. 1988. Characterization of antigen 
receptor response elements within the interleukin-2 enhancer. Mol 
Cell Biol. 8:1715. 
54. Kang, S. M., B. Beverly, A. C. Tran, K. Brorson, R. H. 
Schwartz, and M. J. Lenardo. 1992. Transactivation by AP-1 is a 
molecular target of T cell clonal anergy. Science 257:1134. 
55. Serfling, E., R. Barthelmas, I. Pfeuffer, B. Schenk, S. Zarius, R. 
Swoboda, F. Mercurio, and M. Karin. 1989. Ubiquitous and 
lymphocyte-specific factors are involved in the induction of the 
mouse interleukin 2 gene in T lymphocytes. EMBO J. 8:465. 
56. Higuchi, M., and B. B. Aggarwal. 1993. Okadaic acid induces 
down-modulation and shedding of tumor necrosis factor receptors. 
Comparison with another tumor promoter, phorbol ester. J. Biol. 
Chem. 268:5624. 
Address reprint requests to: 
PDDr. W.Falk 
Department of Internal Medicine I 
University of Regensburg 
93042 Regensburg, Germany 
Received for publication February 18, 1994; accepted March 8, 
1994. 
